GCM
CTMX icon

Graham Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Graham Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-45,449
Closed -$121K – 1047
2022
Q1 		$121K Buy
+45,449
New +$175K ﹤0.01% 856

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Graham Capital Management's CTMX Position: Q2 2022 in Review

Graham Capital Management sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 45,449 shares — an estimated $121K sold.

Graham Capital Management first reported a position in CTMX in Q1 2022 and held it in 1 quarter. The position peaked at $121K in Q1 2022. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • Graham Capital Management reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Graham Capital Management sold 45,449 CytomX Therapeutics shares in Q2 2022, an estimated $121K.
  • Graham Capital Management first reported a position in CytomX Therapeutics in Q1 2022 and held it in 1 quarter.
  • Graham Capital Management's CytomX Therapeutics position peaked at $121K in Q1 2022.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on Graham Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.